Transgenomic, Inc. (TBIO)

0.44
NASDAQ
Prev Close 0.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.42 / 1.65
Exchange NASDAQ
Shares Outstanding 22.85B
Market Cap 10.28M
Div & Yield N.A. (N.A)

Latest News

Transgenomic Accelerates Commercialization Of ICE COLD-PCR (ICP) Amid Plans To Expand Cancer Product Line Ten-Fold

Transgenomic Accelerates Commercialization Of ICE COLD-PCR (ICP) Amid Plans To Expand Cancer Product Line Ten-Fold

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) , today announced plans to expand its ICE COLD-PCR (ICP)-powered cancer assays ten-fold over the next 18 months, targeting a portfolio of more than 200 exons/mutations expected to...

Transgenomic Releases New Data At ASCO 2016 Confirming Concordance Of ICE COLD-PCR (ICP) Liquid And Tissue Biopsies

Transgenomic Releases New Data At ASCO 2016 Confirming Concordance Of ICE COLD-PCR (ICP) Liquid And Tissue Biopsies

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO), today announced that it is unveiling new data at the American Society for Clinical Oncology (ASCO) 2016 Annual Meeting further confirming the utility, speed and efficiency of its...

Trade These 5 Stocks Now to Catch Big Breakout Gains

Trade These 5 Stocks Now to Catch Big Breakout Gains

These five stocks are setting up to break about and trade higher from current levels.

Transgenomic Reports First Quarter 2016 Financial Results

Transgenomic Reports First Quarter 2016 Financial Results

Transgenomic, Inc. (NASDAQ: TBIO) today reported financial results for the first quarter ended March 31, 2016, and provided a business update.

Transgenomic To Hold First Quarter 2016 Results Conference Call On May 24, 2016 At 9:00 AM EDT

Transgenomic To Hold First Quarter 2016 Results Conference Call On May 24, 2016 At 9:00 AM EDT

Transgenomic, Inc. (NASDAQ: TBIO), today announced that the company will hold its First Quarter 2016 Financial Results and Business Update Conference Call on May 24, 2016 at 9:00 AM EDT.

Transgenomic Study Data Shows 100% Concordance Between ICE COLD-PCR™ (ICP) Liquid Biopsies And Conventional Tissue Biopsy Results; ICP Also Identifies More Tumor Mutations Than Conventional Methods

Transgenomic Study Data Shows 100% Concordance Between ICE COLD-PCR™ (ICP) Liquid Biopsies And Conventional Tissue Biopsy Results; ICP Also Identifies More Tumor Mutations Than Conventional Methods

Transgenomic, Inc. (NASDAQ:TBIO) , today announced new concordance study data confirming the superior performance of its ICE COLD-PCR ™ (ICP) enrichment technology over standard biopsied tissue PCR results for...

Transgenomic Unveils The First Rapid Turnaround Liquid Biopsy Metastatic Breast Cancer Panel At AACR 2016 Annual Meeting

Transgenomic Unveils The First Rapid Turnaround Liquid Biopsy Metastatic Breast Cancer Panel At AACR 2016 Annual Meeting

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) , today announced that it is unveiling its new Breast Cancer Analysis Panel this week at the 2016 American Association for Cancer Research (AACR) Annual Meeting.

Transgenomic Reports Full Year 2015 Financial Results

Transgenomic Reports Full Year 2015 Financial Results

Transgenomic, Inc. (NASDAQ: TBIO) today is reporting financial results for the year ended December 31, 2015, and providing a business update.

Transgenomic To Hold Full Year Financial Results Conference Call On April 14, 2016 At 5:00 PM ET

Transgenomic To Hold Full Year Financial Results Conference Call On April 14, 2016 At 5:00 PM ET

Transgenomic, Inc. (NASDAQ: TBIO), today announced that the company will hold its Fourth Quarter and Year-End 2015 Financial Results and Business Update Conference Call on Thursday, April 14, 2016 at 5:00 PM ET.

Transgenomic To Present Data Confirming Utility Of ICE COLD-PCR Liquid Biopsy Technology At American Association For Cancer Research 2016 Annual Meeting

Transgenomic To Present Data Confirming Utility Of ICE COLD-PCR Liquid Biopsy Technology At American Association For Cancer Research 2016 Annual Meeting

Transgenomic, Inc. (NASDAQ: TBIO), today announced that company scientists will present new data at the upcoming American Association for Cancer Research (AACR) 2016 Annual Meeting highlighting the utility of its ICE...

Transgenomic Launches First Commercially Available Assay For Ultra Low Level Detection Of EGFR C797S Mutations That Predict Resistance To Third Generation Kinase Therapies For Lung Cancer

Transgenomic Launches First Commercially Available Assay For Ultra Low Level Detection Of EGFR C797S Mutations That Predict Resistance To Third Generation Kinase Therapies For Lung Cancer

Transgenomic, Inc. (NASDAQ: TBIO) today announced the launch of its EGFR C797S Mutation Detection Assay based on the company's ICE COLD-PCR ™ (ICP) technology.

Transgenomic Launches New MX-ICP Liquid Biopsy Tests For Comprehensive Detection Of Colorectal And Melanoma Tumor Mutations

Transgenomic Launches New MX-ICP Liquid Biopsy Tests For Comprehensive Detection Of Colorectal And Melanoma Tumor Mutations

Transgenomic, Inc. (NASDAQ:TBIO) today announced the launch of its MX-ICP CRC Analysis and MX-ICP Melanoma Analysis, two new liquid biopsy cancer panels based on the company's Multiplexed ICE COLD-PCR ™ (MX-ICP)...

Transgenomic Highlights Unique Advantages Of Multiplexed ICE COLD-PCR™ At Personalized Medicine World Conference

Transgenomic Highlights Unique Advantages Of Multiplexed ICE COLD-PCR™ At Personalized Medicine World Conference

Transgenomic, Inc. (NASDAQ:TBIO) today announced that Ben Legendre, Jr.

Transgenomic Launches New MX-ICP Panels For Liquid Biopsy Detection Of RAS And PIK3CA Tumor Mutations

Transgenomic Launches New MX-ICP Panels For Liquid Biopsy Detection Of RAS And PIK3CA Tumor Mutations

Transgenomic, Inc. (NASDAQ: TBIO) today announced the launch of the MX-ICP RAS Analysis and the MX-ICP PIK3CA Analysis, two new cancer panels based on the company's Multiplexed ICE-COLD PCR ™ (MX-ICP) technology.

Transgenomic Announces Private Placement Financing

Transgenomic Announces Private Placement Financing

Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced that it raised gross proceeds of...

Transgenomic Announces Conversion Of Series A And B Preferred Securities And Extension Of Loan Maturity Date

Transgenomic Announces Conversion Of Series A And B Preferred Securities And Extension Of Loan Maturity Date

Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced that it has moved to simplify and...

Transgenomic Awarded NIH Grant To Augment Multiplexing Capabilities Of ICE COLD-PCR™ Technology In Collaboration With Dana-Farber Cancer Institute

Transgenomic Awarded NIH Grant To Augment Multiplexing Capabilities Of ICE COLD-PCR™ Technology In Collaboration With Dana-Farber Cancer Institute

Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced that it has been awarded a two-year Small...

Transgenomic Reports US Insurers Covering More Than 110 Million Lives Are Providing Reimbursement For Its Genomic Cancer Tests

Transgenomic Reports US Insurers Covering More Than 110 Million Lives Are Providing Reimbursement For Its Genomic Cancer Tests

Transgenomic, Inc. (NASDAQ: TBIO) today reported on the status of insurance reimbursement for its genomic cancer tests currently available for the detection of key mutations in lung cancer and colorectal cancer.

Transgenomic Finalizes Divestment Of Its Genetic Assays & Platforms Business Unit

Transgenomic Finalizes Divestment Of Its Genetic Assays & Platforms Business Unit

Transgenomic, Inc. (NASDAQ: TBIO) today announced that it has completed the divestment of its Genetic Assays & Platforms (GAP) Business Unit to ADSTEC Corporation, and one of its affiliates (ADSTEC).

Transgenomic Reports Third Quarter 2015 Financial Results

Transgenomic Reports Third Quarter 2015 Financial Results

Transgenomic, Inc. (NASDAQ: TBIO) today reported financial results for the third quarter ended September 30, 2015, and provided a business update.

Transgenomic To Hold Third Quarter Financial Results Conference Call On November 12, 2015 At 5:00PM ET

Transgenomic To Hold Third Quarter Financial Results Conference Call On November 12, 2015 At 5:00PM ET

Transgenomic, Inc. (NASDAQ:TBIO), today announced that the company will hold its Third Quarter 2015 Financial Results and Business Update Conference Call on Thursday, November 12, 2015 at 5:00 PM ET.

Transgenomic Launches Expanded MX-ICP™ Lung Cancer Analysis Panel For Liquid Biopsy Detection Of Key Actionable Tumor Mutations In Blood

Transgenomic Launches Expanded MX-ICP™ Lung Cancer Analysis Panel For Liquid Biopsy Detection Of Key Actionable Tumor Mutations In Blood

Transgenomic, Inc. (NASDAQ: TBIO) today announced the launch of its new comprehensive Multiplexed ICE-COLD PCR ™ (MX-ICP) Non-Small Cell Lung Cancer (NSCLC) Analysis panel that covers the key actionable mutations...

Transgenomic Launches New Genetic Testing Service For Diagnosis Of Charcot-Marie-Tooth Syndrome

Transgenomic Launches New Genetic Testing Service For Diagnosis Of Charcot-Marie-Tooth Syndrome

Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced the launch of its CMT NGS Panel for the...

Transgenomic Reports Poster Presentation At CAP '15 Highlighting Joint Project To Detect Actionable Mutations In Tumors From Metastatic Colorectal Cancer Patients

Transgenomic Reports Poster Presentation At CAP '15 Highlighting Joint Project To Detect Actionable Mutations In Tumors From Metastatic Colorectal Cancer Patients

Transgenomic, Inc. (NASDAQ: TBIO) today announced that it presented a poster last week at CAP '15, the annual meeting of the College of American Pathologists.

Transgenomic Signs Binding Term Sheet To Divest Genetic Assays & Platforms Business Unit

Transgenomic Signs Binding Term Sheet To Divest Genetic Assays & Platforms Business Unit

Transgenomic, Inc. (NASDAQ: TBIO) today announced that it has entered into a definitive and binding term sheet to divest its Genetic Assays & Platforms (GAP) Business Unit to ADSTEC Corporation, a privately held...

Transgenomic Announces First License For Commercial Rights To Its Liquid Biopsy Technology In Australia To University Of Melbourne

Transgenomic Announces First License For Commercial Rights To Its Liquid Biopsy Technology In Australia To University Of Melbourne

Transgenomic, Inc. (NASDAQ: TBIO), today announced that it has granted a license to the University of Melbourne to use its Multiplexed ICE COLD-PCR™ (MX-ICP) technology for a number of research and clinical...